首页> 外文期刊>Toxicology and Applied Pharmacology >Assessment of herbal medicinal products: challenges, and opportunities to increase the knowledge base for safety assessment.
【24h】

Assessment of herbal medicinal products: challenges, and opportunities to increase the knowledge base for safety assessment.

机译:草药产品的评估:挑战和增加安全评估知识基础的机会。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Although herbal medicinal products (HMP) have been perceived by the public as relatively low risk, there has been more recognition of the potential risks associated with this type of product as the use of HMPs increases. Potential harm can occur via inherent toxicity of herbs, as well as from contamination, adulteration, plant misidentification, and interactions with other herbal products or pharmaceutical drugs. Regulatory safety assessment for HMPs relies on both the assessment of cases of adverse reactions and the review of published toxicity information. However, the conduct of such an integrated investigation has many challenges in terms of the quantity and quality of information. Adverse reactions are under-reported, product quality may be less than ideal, herbs have a complex composition and there is lack of information on the toxicity of medicinal herbs or their constituents. Nevertheless, opportunities exist to capitalise on newer information to increase the current body of scientific evidence. Novel sources of information are reviewed, such as the use of poison control data to augment adverse reaction information from national pharmacovigilance databases, and the use of more recent toxicological assessment techniques such as predictive toxicology and omics. The integration of all available information can reduce the uncertainty in decision making with respect to herbal medicinal products. The example of Aristolochia and aristolochic acids is used to highlight the challenges related to safety assessment, and the opportunities that exist to more accurately elucidate the toxicity of herbal medicines.
机译:尽管公众已经将草药产品(HMP)视为相对较低的风险,但是随着HMP使用的增加,人们已经越来越认识到与此类产品相关的潜在风险。潜在危害可能通过草药的固有毒性以及污染,掺假,植物误认以及与其他草药产品或药物的相互作用而发生。 HMP的法规安全性评估既要评估不良反应情况,也要审查已发布的毒性信息。然而,进行这样的综合调查在信息的数量和质量方面有许多挑战。不良反应报告不足,产品质量可能不理想,草药成分复杂,缺乏有关草药或其成分毒性的信息。尽管如此,仍有机会利用更新的信息来增加当前的科学证据。审查了新的信息来源,例如使用毒物控制数据来增加来自国家药物警戒数据库的不良反应信息,以及使用最新的毒理学评估技术,例如预测毒理学和组学。所有可用信息的整合可以减少有关草药产品决策的不确定性。马兜铃酸和马兜铃酸的例子用于强调与安全性评估有关的挑战,以及存在的机会,可以更准确地阐明草药的毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号